Antinociception induced by rosuvastatin in mice: Modulation by opioid receptor antagonists, risperidone and l-name
1 Cardiovascular Department, Clinical Hospital, University of Chile, Santiago, 8380000, Chile.
2 Pharmacology Program, Institute of Biomedical Science (ICBM), Faculty of Medicine, University of Chile, Santiago, 8380000, Chile.
3 Office of Scientific Research Support (OAIC), Clinical Hospital, University of Chile, Santiago, 8380000, Chile.
4 Faculty of Medicine, Universidad del Desarrollo, German Clinic, Santiago, Chile.
5 Department of Neuroscience, Faculty of Medicine, University of Chile, Santiago, 8380000, Chile.
Research Article
GSC Advanced Research and Reviews, 2024, 18(03), 379–387.
Article DOI: 10.30574/gscarr.2024.18.3.0113
Publication history:
Received on 05 February 2024; revised on 19 March 2024; accepted on 22 March 2024
Abstract:
Statins are widely used in cardiovascular disease as cholesterol lowering drugs. However, they also have other actions (pleiotropic effects) including antiproliferative, antithrombotic, neuroprotective, immunomodulatory, anti-inflammatory and antinociceptive activity. The aim of this study was to determine the antinociception properties of rosuvastatin in two murine models of pain and the involvement of opioid antagonists (naltrexone, naltrindole, norbinaltorphimine), risperidone, and L-NAME (L-NG-nitro arginine methyl ester) in this effect. Rosuvastatin was chosen among available statins because it is commonly prescribed and has high potency, efficacy, and an acceptable safety profile. Rosuvastatin antinociception was evaluated in the acetic acid writhing test and the formalin hind paw test by dose-response curves, before and after the i.p. administration of opioid antagonists, risperidone, and L-NAME. This work demonstrates that the assayed drugs modulate the antinociceptive effect of rosuvastatin in both experimental murine pain tests. The antinociception effect described for rosuvastatin may be due to a particular modulation induced by the opioid antagonists, risperidone and L-NAME. Given the broad effects of rosuvastatin, the results of this study may have novel clinical implications in the therapy of pain.
Keywords:
Rosuvastatin; Analgesia; Opioid antagonists; Risperidone; L-NAME
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
